Elevation Wealth Partners’s Cymabay Therapeutics CBAY Stock Holding History

Elevation Wealth Partners’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30	Closed	-$448	–	514
2023 Q4	$448	Hold	30	–	–	﹤0.01%	414
2023 Q3	$448	Buy	+30	New	+$398	﹤0.01%	313

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Elevation Wealth Partners's CBAY Position: Q1 2024 in Review

Elevation Wealth Partners sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 30 shares — an estimated $448 sold.

Elevation Wealth Partners first reported a position in CBAY in Q3 2023 and held it in 2 quarters. The position peaked at $448 in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Elevation Wealth Partners reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Elevation Wealth Partners sold 30 Cymabay Therapeutics shares in Q1 2024, an estimated $448.
Elevation Wealth Partners first reported a position in Cymabay Therapeutics in Q3 2023 and held it in 2 quarters.
Elevation Wealth Partners's Cymabay Therapeutics position peaked at $448 in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Elevation Wealth Partners's 13F filing for Q1 2024, filed 19 Apr 2024.